Botox and rehab

Phase 1Small molecule

EEmory University

Botox and rehab is one of 32 small molecule programs targeting Spasticity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SpasticityActive, not recruiting

SpasticityPhase 1

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Spasticity

#DrugCompanyPhaseTrials

Lioresal

Novartis

Approved

4 2

Namenda

AbbVie

Approved

1 3

Cesamet

BBausch Health Americas, Inc.

Approved

—4

Zanaflex

LLegacy Health System

Approved

—5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

4 6

Meditoxin

MMedy-Tox

Approved

1 7

Botox

AbbVie

Phase 3

8 8

Onabont-a

GSK1358820

2 10

Sativex

Jazz Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spasticity1 trial

Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients

Completed·EEmory University·Phase 1·NCT00565201·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Botox and rehab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Botox and rehab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Botox and rehab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emory University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEmory University

Botox and rehab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spasticity1 trial

References

Drug Info

Quick Facts

Related News